advertisement

---

Myers JS 17

Showing records 1 to 17 | Display all abstracts from Myers JS

95894 The effectiveness and safety profile of netarsudil 0.02% in glaucoma treatment: real-world 6-month outcomes
Shiuey EJ
Graefe's Archive for Clinical and Experimental Ophthalmology 2022; 260: 967-974

---

95667 Lessons Learned From 2 Large Community-based Glaucoma Screening Studies
Kolomeyer NN; Kolomeyer NN
Journal of Glaucoma 2021; 30: 875-877

---

95894 The effectiveness and safety profile of netarsudil 0.02% in glaucoma treatment: real-world 6-month outcomes
Mehran NA
Graefe's Archive for Clinical and Experimental Ophthalmology 2022; 260: 967-974

---

95667 Lessons Learned From 2 Large Community-based Glaucoma Screening Studies
Katz LJ
Journal of Glaucoma 2021; 30: 875-877

---

95894 The effectiveness and safety profile of netarsudil 0.02% in glaucoma treatment: real-world 6-month outcomes
Ustaoglu M
Graefe's Archive for Clinical and Experimental Ophthalmology 2022; 260: 967-974

---

95667 Lessons Learned From 2 Large Community-based Glaucoma Screening Studies
Hark LA
Journal of Glaucoma 2021; 30: 875-877

---

95894 The effectiveness and safety profile of netarsudil 0.02% in glaucoma treatment: real-world 6-month outcomes
Zhang Q
Graefe's Archive for Clinical and Experimental Ophthalmology 2022; 260: 967-974

---

95667 Lessons Learned From 2 Large Community-based Glaucoma Screening Studies
Wahl M
Journal of Glaucoma 2021; 30: 875-877

---

95894 The effectiveness and safety profile of netarsudil 0.02% in glaucoma treatment: real-world 6-month outcomes
Razeghinejad R
Graefe's Archive for Clinical and Experimental Ophthalmology 2022; 260: 967-974

---

95667 Lessons Learned From 2 Large Community-based Glaucoma Screening Studies
Gajwani P
Journal of Glaucoma 2021; 30: 875-877

---

95894 The effectiveness and safety profile of netarsudil 0.02% in glaucoma treatment: real-world 6-month outcomes
Shukla AG
Graefe's Archive for Clinical and Experimental Ophthalmology 2022; 260: 967-974

---

95667 Lessons Learned From 2 Large Community-based Glaucoma Screening Studies
Aziz K
Journal of Glaucoma 2021; 30: 875-877

---

95894 The effectiveness and safety profile of netarsudil 0.02% in glaucoma treatment: real-world 6-month outcomes
Shukla AG; Kolomeyer NN
Graefe's Archive for Clinical and Experimental Ophthalmology 2022; 260: 967-974

---

95667 Lessons Learned From 2 Large Community-based Glaucoma Screening Studies
Myers JS
Journal of Glaucoma 2021; 30: 875-877

---

95894 The effectiveness and safety profile of netarsudil 0.02% in glaucoma treatment: real-world 6-month outcomes
Kolomeyer NN; Myers JS
Graefe's Archive for Clinical and Experimental Ophthalmology 2022; 260: 967-974

---

95667 Lessons Learned From 2 Large Community-based Glaucoma Screening Studies
Friedman DS
Journal of Glaucoma 2021; 30: 875-877

---

95894 The effectiveness and safety profile of netarsudil 0.02% in glaucoma treatment: real-world 6-month outcomes
Lee D
Graefe's Archive for Clinical and Experimental Ophthalmology 2022; 260: 967-974

---